Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Date of Publication:

December 18, 2018

Pubmed Link:

Does addition of heated IP chemo at the time of interval cytoreduction improve survival in advanced ovarian cancer?

Control Arm(s):

Interval cytoreduction

3 cycles of Carboplatin (AUC 5/6) + Paclitaxel (175 mg/m2)

Experimental Arm(s):

Interval cytoreduction + HIPEC (100 mg/m2 cisplatin x 90 minutes at 40°C)

3 cycles of Carboplatin (AUC 5/6) + Paclitaxel (175 mg/m2)

Primary End Point:


Inclusion Criteria:

Stage III ovarian cancer

3 cycles of neoadjuvant carbo/taxol with at least partial response

Residual disease ≤1cm

Exclusion Criteria:

Surgery + HIPEC (n=122) vs. Surgery (n=123)

median f/u: 4.7 yrs

Median PFS: 14.2 vs 10.7 mos (SS)

median OS: 45.7  vs 33.9 mos (SS)

Median duration of surgery: 338 vs 192 minutes

Median hospital LOS: 10 vs 8 days (1 day in ICU specified by protocol)

Toxicities were balanced between groups

No differences in timing of chemo restart or rates of post-surgery chemo completion


Addition of HIPEC to complete or optimal interval cytoreductive surgery resulted in longer PFS and OS than surgery alone in women with advanced ovarian cancer

Kevin McCool, OTF